APA (7th ed.) Citation

Guo, W., Yu, X., Lu, Z., Li, Y., Wu, C., Gu, L., . . . Guo, L. (2026). Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma. British Journal of Cancer, 134(11), 1557. https://doi.org/10.1038/s41416-026-03401-5

Chicago Style (17th ed.) Citation

Guo, Wan-Ping, et al. "Incorporating Early CfEBV DNA Clearance into Clinical Risk Stratification to Tailor Induction Chemotherapy Cycles for Locoregionally Advanced Nasopharyngeal Carcinoma." British Journal of Cancer 134, no. 11 (2026): 1557. https://doi.org/10.1038/s41416-026-03401-5.

MLA (9th ed.) Citation

Guo, Wan-Ping, et al. "Incorporating Early CfEBV DNA Clearance into Clinical Risk Stratification to Tailor Induction Chemotherapy Cycles for Locoregionally Advanced Nasopharyngeal Carcinoma." British Journal of Cancer, vol. 134, no. 11, 2026, p. 1557, https://doi.org/10.1038/s41416-026-03401-5.